Publicacións en colaboración con investigadores/as de Hospital Xeral Calde (7)

2011

  1. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

2008

  1. Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 11, pp. 739-744

  2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212

2005

  1. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438